Haynes D, Strunck JL, Topham CA, et al. - In this single-arm trial involving 12 adults (mean [SD] age, 49.8 [15.1] years; 8 male [67%]), researchers examined the clinical response and safety of ixekizumab in treating pityriasis rubra pilaris. Study participants were enrolled between June 2018 and April 2019, with 11 completing the full course of intervention. According to results, ixekizumab has been linked to reduced clinical signs and symptoms of pityriasis rubra pilaris in a subset of patients, including those in whom other systemic therapies have failed. There have been no serious adverse events.